The Slow Death of a Blockbuster
This article was originally published in RPM Report
Executive Summary
Bad news continues to mount for erythropoiesis-stimulating agents (ESAs), the flagship products of the biotechnology industry. Far from developing new markets, postmarket clinical trials by Amgen and J&J continue to point towards a much smaller appropriate patient population for Aranesp and Procrit.
You may also be interested in...
De-Risking Headline Risk: Merck Media Strategy Helps Company Ride Out ARBITER Data
A negative, head-to-head study questioning the role of Vytorin is presented at AHA: that sounds like a replay of the ENHANCE disaster. But here's the twist: Merck shares rallied after the data were released. What changed?
De-Risking Headline Risk: Merck Media Strategy Helps Company Ride Out ARBITER Data
A negative, head-to-head study questioning the role of Vytorin is presented at AHA: that sounds like a replay of the ENHANCE disaster. But here's the twist: Merck shares rallied after the data were released. What changed?
Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab
When it comes to Amgen, all eyes are on denosumab. That's as it should be: Amgen's future rides on the potential blockbuster. But investors shouldn't lose sight of Amgen's past and present: how the company manages the continued threats to Aranesp have important lessons for the biopharma sector as a whole-and for denosumab too.